Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2,3-dihydro-n-2-propynyl-1h-inden-1-amine-(1r)-hydrochloride
2. Agn 1135
3. Agn-1135
4. Azilect
5. N-2-propynyl-1-indanamine
6. N-propargyl-1-aminoindan Mesylate
7. Rasagiline
8. Rasagiline Hydrochloride
9. Tvp 101
10. Tvp 1022
11. Tvp-101
12. Tvp-1022
13. Tvp1022
1. 161735-79-1
2. Azilect
3. Rasagiline Mesilate
4. Tvp-1012
5. Agilect
6. (r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine Methanesulfonate
7. Rasagiline Methanesulfonate
8. Rasagiline Mesylate [usan]
9. Rasagiline (mesylate)
10. Rasagline Ratiopharm
11. Rasagiline (as Mesilate)
12. Lh8c2ji290
13. (r)-n-2-propynyl-1-indanamine Methanesulfonate
14. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, Methanesulfonate
15. Methanesulfonic Acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine
16. Ncgc00168774-01
17. Azilect (tn)
18. Mfcd08460604
19. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, Methanesulfonate
20. Rasagiline Mesilate (jan)
21. Rasagiline Mesylate (usan)
22. Dsstox_cid_27826
23. Dsstox_rid_82589
24. Dsstox_gsid_47848
25. Rasagiline Mesilate [jan]
26. Tvp1012
27. Cas-161735-79-1
28. Tvp 1012
29. Unii-lh8c2ji290
30. C12h13n.ch3so3h
31. Schembl158439
32. (1r)-2,3-dihydro-n-2-propynyl-1h-inden-1-amine Methanesulfonate
33. (r)-2,3-dihydro-n-2-propynyl-1-indenamine Mesylate
34. Chembl1201142
35. Dtxsid8047848
36. Hms3884d07
37. Rasagiline Mesylate [vandf]
38. (1r)-2,3-dihydro-n-2-propyn-1-yl-1h-inden-1-amine Mesylate
39. Act06733
40. Rasagiline Mesilate [mart.]
41. Tox21_112635
42. Ac-724
43. Rasagiline Mesylate [who-dd]
44. S2102
45. Akos005145768
46. Rasagiline Mesylate, >=98% (hplc)
47. Tox21_112635_1
48. Bs-1009
49. Ccg-267122
50. Tv 1012
51. 1h-inden-1-amine, 2,3-dihydro-n-2-propyn-1-yl-, (1r)-, Methanesulfonate (1:1)
52. Rasagiline Methanesulfonate [mi]
53. Ncgc00168774-02
54. Rasagiline Mesylate [orange Book]
55. (+)-agn-1135
56. Hy-14605
57. R0213
58. D02562
59. 735r791
60. Q-101873
61. Q27282989
62. (r)-n-2-propynyl-1-indanamine Methanesulphonate
63. Z1820079046
64. (1r)-2,3-dihydro-n-2-propynyl-1h-in Den-1-amine Methanesulfonate
65. (r)-n-(prop-2-ynyl)-2,3-dihydro-1h-inden-1-amine Methanesulfonate
66. (1r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine; Methanesulfonic Acid
67. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, Methanesulphonate
Molecular Weight | 267.35 g/mol |
---|---|
Molecular Formula | C13H17NO3S |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Exact Mass | 267.09291458 g/mol |
Monoisotopic Mass | 267.09291458 g/mol |
Topological Polar Surface Area | 74.8 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 305 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Azilect |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.5mg base; eq 1mg base |
Market Status | Prescription |
Company | Teva |
2 of 4 | |
---|---|
Drug Name | Rasagiline mesylate |
PubMed Health | Rasagiline (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 0.5mg base; 0.5mg; 1mg; eq 1mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharma; Apotex |
3 of 4 | |
---|---|
Drug Name | Azilect |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.5mg base; eq 1mg base |
Market Status | Prescription |
Company | Teva |
4 of 4 | |
---|---|
Drug Name | Rasagiline mesylate |
PubMed Health | Rasagiline (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 0.5mg base; 0.5mg; 1mg; eq 1mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharma; Apotex |
Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Monoamine Oxidase Inhibitors
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
N04BD02
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-900
Start Marketing Date : 2010-01-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17075
Submission : 2004-01-07
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-20
Pay. Date : 2016-06-16
DMF Number : 30600
Submission : 2016-06-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22782
Submission : 2009-05-15
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-06-28
Pay. Date : 2016-06-08
DMF Number : 22366
Submission : 2008-12-30
Status : Active
Type : II
Date of Issue : 2019-10-11
Valid Till : 2022-07-02
Written Confirmation Number : WC-0157
Address of the Firm :
NDC Package Code : 65015-775
Start Marketing Date : 2015-02-19
End Marketing Date : 2026-12-01
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2019-04-10
Registration Number : Su289-6-ND
Manufacturer Name : Mylan Laboratories Limited@Viyash Life Sciences Private Limited
Manufacturer Address : Plot No.1A/2, MIDC Industrial Estate Taloja, Panvel, Dist : Raigad Maharashtra Raigad 410208 Maharashtra State, India@Plot No.1-A/2 & Plot No. 1-A/3, MIDC Taloja Industrial Area, Taloja - 410208 Taluka: Panvel, District RAIGAD. Maharashtra, India
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-06
Pay. Date : 2013-02-21
DMF Number : 24159
Submission : 2010-09-01
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-03
Pay. Date : 2012-12-20
DMF Number : 26599
Submission : 2012-12-21
Status : Active
Type : II
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm :
NDC Package Code : 66039-878
Start Marketing Date : 2013-05-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Chong Kun Dang Co., Ltd.
Registration Date : 2020-07-15
Registration Number : Su434-9-ND(4)
Manufacturer Name : Glenmark Life Sciences Limited.
Manufacturer Address : Plot No 3109, GIDC Industrial Estate, Ankleshwar - 393 002, Dist. Bharuch, Gujarat State, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23687
Submission : 2010-05-07
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?